Alcon to Acquire Neurotech for $550 Million, Gaining Ophthalmic Cell Therapy ENCELTO

On October 20, 2026, Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million, with the core assets being the company's ophthalmic cell therapy platform and ENCELTO, which received FDA approval in March 2025. The deal may also include additional payments tied to commercialization milestones. ENCELTO treats macular telangiectasia type 2 in adults and is the first approved therapy for this indication in the United States.